It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Within mosquito vector populations, infectious mosquitoes are the ones completing the transmission of pathogens to susceptible hosts and they are, consequently, of great epidemiological interest. Mosquito infection by malaria parasites has been shown to affect several traits of mosquito physiology and behavior, and could interplay with the efficacy of control tools. In this study, we evaluated, in pyrethroid resistant Anopheles gambiae, the effect of mosquito infection with the human malaria parasite Plasmodium falciparum on the efficacy of nets treated with either the insecticide deltamethrin or the repellent DEET, measuring (i) mosquito success to pass through the net, (ii) blood-feeding on a host and (iii) chemicals-induced mortality. Infection of mosquitoes at non-infectious stage did not affect their success to pass through the net, to blood-feed, nor chemicals-induced mortality. At infectious stage, depending on replicates, infected mosquitoes had higher mortality rates than uninfected mosquitoes, with stronger effect in presence of DEET. This data evidenced a cost of infection on mosquito survival at transmissible stages of infection, which could have significant consequences for both malaria epidemiology and vector control. This stresses the need for understanding the combined effects of insecticide resistance and infection on the efficacy on control tools.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France (GRID:grid.462603.5) (ISNI:0000 0004 0382 3424); CEFE, Univ Paul Valéry Montpellier 3, CNRS, Univ Montpellier, EPHE, IRD, Montpellier, France (GRID:grid.433534.6) (ISNI:0000 0001 2169 1275)
2 Institut Pierre Richet/Institut National de Santé Publique, Bouake, Côte d’Ivoire (GRID:grid.433534.6)
3 MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France (GRID:grid.462603.5) (ISNI:0000 0004 0382 3424)
4 MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France (GRID:grid.462603.5) (ISNI:0000 0004 0382 3424); Institut de Recherches en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (GRID:grid.462603.5)
5 Institut de Recherches en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso (GRID:grid.462603.5)
6 Institut Pierre Richet/Institut National de Santé Publique, Bouake, Côte d’Ivoire (GRID:grid.462603.5)
7 CEFE, Univ Paul Valéry Montpellier 3, CNRS, Univ Montpellier, EPHE, IRD, Montpellier, France (GRID:grid.433534.6) (ISNI:0000 0001 2169 1275)
8 MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France (GRID:grid.462603.5) (ISNI:0000 0004 0382 3424); Institut Pierre Richet/Institut National de Santé Publique, Bouake, Côte d’Ivoire (GRID:grid.462603.5)